Mike Havrilla

New Index of Highly Defensive Market Cap Leaders

23 stock indexes summarized below, tracked at Investars YOU site:
biomedreports.com/blog...


On Jul 14 09:08 AM rusb wrote:

> What happened to ETF Innovators? I cannot find thier web site.

New Index of Highly Defensive Market Cap Leaders

All of the ETF Innovators indexes are featured at my new site and will be tracked at the site in the future, but not initially -- none of the indexes have tickers or associated ETFs/funds yet:
www.biomedreports.com/...

New Index of Highly Defensive Market Cap Leaders

Started last year on 2/1/08
Quarterly Rebalancing
Exchanges within one week of mergers
Will be tracked on daily closing basis at my new website once the web programmer adds this feature, for now the component stocks are listed:
www.biomedreports.com/...



On Feb 26 06:05 PM Anonymous 2 wrote:

> Interesting - but many questions - a few for starters:
> on what day/date did this index start?
> how often would such a portfolio be reallocated to maintain the equal
> weightings?
> "who" (at ETF Innovators ?) and how often would exchanges to take
> place going forward to allow for mergers?

Pharmaceuticals: Pfizer Is a Buy

Abbott has a more diversified mix of businesses with diagnostics/nutrionals as summarized below from their last earnings report:

-global sales growth of 14.8% to $7.3 billion (B)

-pharmaceutical sales ($4.1B) growth of 16.7% led by Humira (a biological agent for autoimmune diseases such as rheumatoid arthritis), which experienced a 48% growth in sales for 1H08 at $1.1B with a forecast for sales of $4.3 billion for 2008

-medical product sales ($1.4B) growth of 14.7% driven by diagnostics sales ($0.9B) growth over 17%

-nutritional sales ($1.2B) growth of 21.3% thanks to strong results in emerging markets

Abbott Labs reported total sales for the first half of 2008 of $14.1B with $6.5B in the USA and $7.6B internationally. The Company posted a diversified mix of healthcare business units with 56.5% of sales from prescription drugs, 16.5% from nutrional products, 12.5% from diagnostics, and about 6.5% from vascular products such as stents. The Company increased its earnings-per-share guidance from a range of $3.20 - $3.25 to $3.24 - $3.28, excluding specified items, reflecting growth of about 15% along with expected sales growth in the mid-teens for the full year.

Pharmaceuticals: Pfizer Is a Buy

Thats why I included link to my previous articles on Pfizer instead of repeating the same thing in this article:
www.google.com/cse?cx=...